Treatment News : Sofosbuvir, Daclatasvir Combo Cures 100% in Hep C Trial

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 29, 2013

Sofosbuvir, Daclatasvir Combo Cures 100% in Hep C Trial

Gilead Sciences’ sofosbuvir and Bristol-Myers Squibb’s daclatasvir, taken with or without ribavirin, cured 100 percent of previously treated participants of hepatitis C virus (HCV) in a recent trial, echoing previous studies of this highly potent combination therapy, Bloomberg Businessweek reports. However, because of the fact that Gilead has opted not to work jointly with BMS on advanced studies of the two drugs in combination, preferring instead to set its sights on a single combination pill of sofosbuvir with the company’s own ledipasvir, it appears unlikely there will ever be a U.S. Food and Drug Administration approval of sofosbuvir and daclatasvir in combination.

The results of the study, which included 41 people with genotype 1 of hep C who had failed an interferon-based therapy including either Victrelis (boceprevir) or Incivek (telaprevir), were presented at the International Liver Congress, the 48th annual meeting of the European Association for the Study of the Liver (EASL) in Amsterdam.

The study did not include those with cirrhosis of the liver, although more than four in five of the participants had moderate fibrosis or higher.

The participants were randomly assigned to receive the NS5A replication complex inhibitor daclatasvir and the nucleotide analog HCV polymerase inhibitor sofosbuvir either with or without ribavirin for 24 weeks.

All 41 of the participants achieved a sustained virologic response (SVR, considered a cure) 24 weeks after completing the therapy. The treatment was generally safe and well tolerated in both arms of the study. Those taking ribavirin reported greater fatigue and gastrointestinal symptoms.

If both drugs are approved as independent agents, physicians will have the option to prescribe them “off-label.”

To read the Bloomberg story, click here.

To read the abstract and see study slides, click here.

Search: Gilead Sciences, sofosbuvir, Bristol-Myers Squibb, daclatasvir, hepatitis C virus, HCV, hep C, Bloomberg Businessweek, U.S. Food and Drug Administration, Victrelis, boceprivir, Incivek, telaprevir, 48th annual meeting of the European Association for the Study of the Liver, EASL.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (3 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.